Is there any difference in ra patients for methotrexate use vs. leflunomide use as a concomitant treatment with biological and targeted synthetic dmards in turkbio registry?

İnanç, NevsunÖzen, GülşenYalçınkaya, YaseminKoca, Süleyman SerdarCan, GerçekKarataş, AhmetYazıcı, AytenCefle, AyşeTufan, AbdurrahmanAkar, ServetŞenel, SonerÖz, BurakAkkoç, NurullahÖnen, Fatoş2024-01-102024-01-102018-06İnanç, N. vd. (2018). ''Is there any difference in ra patients for methotrexate use vs. leflunomide use as a concomitant treatment with biological and targeted synthetic dmards in turkbio registry?''. Annals of the Rheumatic Diseases, 77(Supplement 2), 611-612.0003-4967https://ard.bmj.com/content/77/Suppl_2/611.2https://hdl.handle.net/11452/38944Bu çalışma, 13-16, Haziran 2018 tarihlerinde Amsterdam[Hollanda]’da düzenlenen Congress of the European-League-Against-Rheumatism (EULAR) Kongresi‘nde bildiri olarak sunulmuştur.eninfo:eu-repo/semantics/openAccessRheumatologyIs there any difference in ra patients for methotrexate use vs. leflunomide use as a concomitant treatment with biological and targeted synthetic dmards in turkbio registry?Article00044435100159761161277Supplement 2https://doi.org/10.1136/annrheumdis-2018-eular.5662Rheumatology1468-2060